☆ 4.7 Article

Cost-effectiveness of nivolumab plus ipilimumab versus chemotherapy as first-line therapy in advanced non-small cell lung cancer

INTERNATIONAL IMMUNOPHARMACOLOGY (2023)

Related references

Note: Only part of the references are listed.

Article Pharmacology & Pharmacy

Cost-Effectiveness of Tislelizumab Versus Docetaxel for Previously Treated Advanced Non-Small-Cell Lung Cancer in China

Jinhong Gong et al.

Summary: A study evaluated the cost-effectiveness of Tislelizumab compared to Docetaxel for previously treated NSCLC patients in China. The results showed that Tislelizumab can prolong survival and is a cost-effective option at the current price.

FRONTIERS IN PHARMACOLOGY (2022)

Add to Collection

Article Oncology

Cost-Effectiveness of Nivolumab Plus Chemotherapy vs. Chemotherapy as First-Line Treatment for Advanced Gastric Cancer/Gastroesophageal Junction Cancer/Esophagel Adenocarcinoma in China

Yamin Shu et al.

Summary: This study evaluated the cost-effectiveness of nivolumab plus chemotherapy compared to chemotherapy as first-line therapy for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma. The findings showed that nivolumab plus chemotherapy was not cost-effective and suggested reducing the drug price to improve cost-effectiveness.

FRONTIERS IN ONCOLOGY (2022)

Add to Collection

Article Oncology

Cancer treatment and survivorship statistics, 2022

Kimberly D. Miller et al.

Summary: The number of cancer survivors in the United States is increasing due to population growth, aging, and improved detection and treatment. The most prevalent cancers are prostate, skin melanoma, and colon and rectum for males, and breast, uterine corpus, and thyroid for females. Treatment disparities exist, with Black patients being less likely to be diagnosed with early-stage cancer and having lower surgical receipt rates.

CA-A CANCER JOURNAL FOR CLINICIANS (2022)

Add to Collection

Article Pharmacology & Pharmacy

Cost-Effectiveness of First-Line Nivolumab Plus Ipilimumab Combination Therapy in Advanced Non-Small-Cell Lung Cancer in Japan

Xiuting Mo et al.

Summary: This study evaluated the cost-effectiveness of NIV + IPI combination therapy compared to chemotherapy in the treatment of advanced non-small-cell lung cancer (NSCLC) in Japanese settings. The results showed that compared to chemotherapy, NIV + IPI therapy incurred additional costs and conferred additional QALYs, resulting in an ICER above the willingness-to-pay threshold from the perspective of the Japanese healthcare system. Sensitivity analyses showed generally consistent results.

CLINICAL DRUG INVESTIGATION (2022)

Add to Collection

Article Economics

Cost-effectiveness analysis of nivolumab plus ipilimumab versus platinum-doublet chemotherapy for first-line treatment of stage IV or recurrent non-small cell lung cancer in the United States

Malin Berling et al.

Summary: This study evaluated the cost-effectiveness of nivolumab in combination with ipilimumab compared to platinum-doublet chemotherapy for the first-line treatment of stage IV or recurrent NSCLC. The results showed that nivolumab in combination with ipilimumab had increased survival but higher costs compared to platinum-doublet chemotherapy.

JOURNAL OF MEDICAL ECONOMICS (2022)

Add to Collection

Article Medicine, General & Internal

First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial

Paul Baas et al.

Summary: Nivolumab plus ipilimumab demonstrated significant improvement in overall survival compared to standard chemotherapy for unresectable malignant pleural mesothelioma. This first-in-class treatment regimen has been approved for previously untreated patients in the USA and showed promising outcomes with manageable adverse events.

LANCET (2021)

Add to Collection

Article Oncology

Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

Hyuna Sung et al.

Summary: The global cancer burden in 2020 saw an estimated 19.3 million new cancer cases and almost 10.0 million cancer deaths. Female breast cancer surpassed lung cancer as the most commonly diagnosed cancer, while lung cancer remained the leading cause of cancer death. These trends are expected to rise in 2040, with transitioning countries experiencing a larger increase compared to transitioned countries due to demographic changes and risk factors associated with globalization and a growing economy. Efforts to improve cancer prevention measures and provision of cancer care in transitioning countries will be crucial for global cancer control.

CA-A CANCER JOURNAL FOR CLINICIANS (2021)

Add to Collection

Article Medicine, General & Internal

Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma

Dan Su et al.

Summary: Cost-effectiveness evaluation of atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma from the US payer perspective showed that the treatment is unlikely to be cost-effective compared with sorafenib. Lowering the prices of atezolizumab and bevacizumab may enhance cost-effectiveness, and tailoring treatments based on individual patient factors could also improve economic outcomes.

JAMA NETWORK OPEN (2021)

Add to Collection

Article Pharmacology & Pharmacy

Cost-Effectiveness of Domestic PD-1 Inhibitor Camrelizumab Combined With Chemotherapy in the First-Line Treatment of Advanced Nonsquamous Non-Small-Cell Lung Cancer in China

Liu Qiao et al.

Summary: The study found that using first-line CPC is a cost-effective treatment compared to traditional PC chemotherapy for Chinese patients with advanced nonsquamous NSCLC, while first-line PPP is not a cost-effective option compared to first-line CPC. These results support the widespread use of first-line CPC in China and encourage the development of domestic cancer drugs.

FRONTIERS IN PHARMACOLOGY (2021)

Add to Collection

Article Oncology

Cost-Effectiveness Analysis of Gefitinib Plus Chemotherapy versus Gefitinib Alone for Advanced Non-Small-Cell Lung Cancer with EGFR Mutations in China

Yamin Shu et al.

Summary: The study evaluated the cost-effectiveness of gefitinib plus chemotherapy versus gefitinib alone for advanced NSCLC patients with EGFR mutations in China. The base case analysis showed that gefitinib plus chemotherapy was a cost-effective treatment option with an ICER lower than the accepted WTP threshold. Sensitivity analyses confirmed the robustness of the results, demonstrating the advantages of gefitinib plus chemotherapy over gefitinib alone.

CANCER MANAGEMENT AND RESEARCH (2021)

Add to Collection

Article Oncology

Cost-Effectiveness of Nivolumab Plus Ipilimumab With and Without Chemotherapy for Advanced Non-Small Cell Lung Cancer

Szu-Chun Yang et al.

Summary: Based on subgroup and probabilistic analysis, researchers found that first-line N+I or N+I+chemotherapy for metastatic NSCLC patients was not cost-effective from the U.S. health care sector perspective, regardless of PD-L1 expression levels.

FRONTIERS IN ONCOLOGY (2021)

Add to Collection

Article Public, Environmental & Occupational Health

Efficiency of fine scale and spatial regression in modelling associations between healthcare service spatial accessibility and their utilization

Fei Gao et al.

Summary: Healthcare accessibility is a key public health issue that involves potential and realized access dimensions. This study found that spatial accessibility to general practitioners and physiotherapists was associated with shorter hospital stays for elderly patients. Geographically weighted regression performed better than other statistical methods in analyzing this relationship, providing valuable information for healthcare policies and resource allocation.

INTERNATIONAL JOURNAL OF HEALTH GEOGRAPHICS (2021)

Add to Collection

Article Medicine, General & Internal

Cost-effectiveness of Nivolumab-Ipilimumab Combination Therapy for the Treatment of Advanced Non-Small Cell Lung Cancer

P. Travis Courtney et al.

Summary: The study assessed the cost-effectiveness of nivolumab-ipilimumab combination therapy as a first-line treatment for patients with advanced non-small cell lung cancer. Despite the increase in overall survival indicated by clinical trial data, the therapy was not found to be cost-effective at current prices.

JAMA NETWORK OPEN (2021)

Add to Collection

Article Pharmacology & Pharmacy

Cost-Effectiveness of Nivolumab Plus Ipilimumab as First-Line Therapy in Advanced Non-small-cell Lung Cancer

Xuezhi Hao et al.

Summary: The cost-effectiveness analysis of nivolumab plus ipilimumab for advanced non-small cell lung cancer showed that it is a cost-effective option in the United States but not in China. Sensitivity analyses confirmed the robustness of the results.

FRONTIERS IN PHARMACOLOGY (2021)

Add to Collection

Article Pharmacology & Pharmacy

Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab for Advanced Non-Small-Cell Lung Cancer

Xiaomin Wan et al.

Summary: The study suggests that nivolumab plus ipilimumab may be more cost-effective compared to chemotherapy, especially at a WTP threshold of $100,000/QALY to $150,000/QALY. Body weight and overall survival hazard ratio are key variables influencing the cost-effectiveness ratio.

FRONTIERS IN PHARMACOLOGY (2021)

Add to Collection

Article Immunology

Cost-effectiveness analysis of nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced NSCLC

Jiahao Li et al.

IMMUNOTHERAPY (2020)

Add to Collection

Article Oncology

Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib The CheckMate 040 Randomized Clinical Trial

Thomas Yau et al.

JAMA ONCOLOGY (2020)

Add to Collection

Article Oncology

Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab vs. Chemotherapy as First-Line Therapy in Advanced Non-Small Cell Lung Cancer

Huabin Hu et al.

FRONTIERS IN ONCOLOGY (2020)

Add to Collection

Article Medicine, General & Internal

Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

J. Larkin et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

Add to Collection

Article Medicine, General & Internal

Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer

M. D. Hellmann et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

Add to Collection

Article Health Care Sciences & Services

Health state utilities in patients with advanced non-small-cell lung cancer in China

Yunjie Shen et al.

JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH (2018)

Add to Collection

Article Oncology

Health state utilities in non-small cell lung cancer: An international study

Beenish Nafees et al.

ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2017)

Add to Collection

Article Medicine, General & Internal

Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer

H. Borghaei et al.

NEW ENGLAND JOURNAL OF MEDICINE (2015)

Add to Collection

Article Oncology

PARAMOUNT: Final Overall Survival Results of the Phase III Study of Maintenance Pemetrexed Versus Placebo Immediately After Induction Treatment With Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non-Small-Cell Lung Cancer

Luis G. Paz-Ares et al.

JOURNAL OF CLINICAL ONCOLOGY (2013)

Add to Collection

Article Oncology

Postprogression survival for first-line chemotherapy of patients with advanced non-small-cell lung cancer

H. Hayashi et al.

ANNALS OF ONCOLOGY (2012)

Add to Collection

Article Multidisciplinary Sciences

Economic Evaluation of First-Line Treatments for Metastatic Renal Cell Carcinoma: A Cost-Effectiveness Analysis in A Health Resource-Limited Setting

Bin Wu et al.

PLOS ONE (2012)

Add to Collection

Article Health Care Sciences & Services

Improved curve fits to summary survival data: application to economic evaluation of health technologies

Martin W. Hoyle et al.

BMC MEDICAL RESEARCH METHODOLOGY (2011)

Add to Collection

© Peeref 2019-2024. All rights reserved.